Epoetin-associated pure red cell aplasia: past, present, and future considerations
about
An Overview of Current Regulatory Requirements for Approval of Biosimilar InsulinsStandardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortiumBisphosphonates and nonhealing femoral fractures: analysis of the FDA Adverse Event Reporting System (FAERS) and international safety efforts: a systematic review from the Research on Adverse Drug Events And Reports (RADAR) projectWhat do oncologists need to know about biosimilar products?Antidrug Antibodies: B Cell Immunity Against TherapyTools to evaluate the conformation of protein products.Immunogenicity and PK/PD evaluation in biotherapeutic drug development: scientific considerations for bioanalytical methods and data analysis.Use of hematopoietic growth factor in the management of hematological side effects associated to antiviral treatment for HCV hepatitisPharmacotherapy of end-stage renal disease.Mesenchymal stromal cells engineered to express erythropoietin induce anti-erythropoietin antibodies and anemia in allorecipientsEffects of erythropoietin on depressive symptoms and neurocognitive deficits in depression and bipolar disorder.Improved drug-like properties of therapeutic proteins by directed evolution.Biosimilars: Implications for health-system pharmacists.Quality of original and biosimilar epoetin productsIncidence of erythropoietin antibody-mediated pure red cell aplasia: the Prospective Immunogenicity Surveillance Registry (PRIMS).Erythropoietin (EPO) in acute kidney injuryConformational analysis of therapeutic proteins by hydroxyl radical protein footprintingAssociation of Erythropoietin Dose and Route of Administration with Clinical Outcomes for Patients on Hemodialysis in the United StatesHepatitis C virus: a critical appraisal of new approaches to therapy.Linking drugs to obscure illnesses: lessons from pure red cell aplasia, nephrogenic systemic fibrosis, and Reye's syndrome. a report from the Southern Network on Adverse Reactions (SONAR).Evaluating and Reporting the Immunogenicity Impacts for Biological Products--a Clinical Pharmacology PerspectiveResults from the first decade of research conducted by the Research on Adverse Drug Events and Reports (RADAR) project.Recombinant human epoetin beta in the treatment of chemotherapy-related anemia.Delivery of therapeutic proteins.Erythropoietic stimulating agents.Clinical concerns of immunogenicity produced at cellular levels by biopharmaceuticals following their parenteral administration into human body.Non-erythropoietic tissue-protective peptides derived from erythropoietin: WO2009094172.Today's challenges in pharmacovigilance: what can we learn from epoetins?Transduction of human recombinant proteins into mitochondria as a protein therapeutic approach for mitochondrial disorders.Unexpected hematologic effects of biotherapeutics in nonclinical species and in humans.Preclinical models used for immunogenicity prediction of therapeutic proteins.Overview of subsequent entry biologics for the management of inflammatory bowel disease and Canadian Association of Gastroenterology position statement on subsequent entry biologics.Side effects of cytokines approved for therapy.History of Erythropoiesis-Stimulating Agents, the Development of Biosimilars, and the Future of Anemia Treatment in Nephrology.Biosimilars in rheumatic diseases: structural and functional variability that may impact clinical and regulatory decisions.The role of immune tolerance induction in restoration of the efficacy of ERT in Pompe disease.Treatment of anemia in chronic kidney disease: known, unknown, and both.Pure red cell aplasia after treatment of renal anaemia with epoetin theta.Is a Biologic Produced 15 Years Ago a Biosimilar of Itself Today?Iron as the key modulator of hepcidin expression in erythroid antibody-mediated hypoplasia.
P2860
Q26823562-2B74A60F-4651-4E59-9E16-278F26465DFBQ27009385-1ABA9C85-2625-4941-BF96-9B540B341054Q27026618-7E14437F-608B-48E1-B08B-C89BDC08A54CQ28071687-C0B17A07-C005-40E9-92C6-DB332EB9A940Q28082303-B42163C3-4519-479B-AF54-32C0AD2A7DA5Q30402632-E53C9BF7-33F1-4F80-AB32-7B2B8B584AAAQ30716340-F082849A-2C8F-4568-9857-71D205BB6138Q33394544-1949F6B3-7886-4889-A0CE-D8EE2DB2552BQ33531889-564EF414-27D1-43A0-94EB-70208086CB63Q33713301-DCABDA31-01ED-4F73-A9F4-272FB4348D4BQ34258204-6BA8223D-399F-4656-AB56-1844CD4E1997Q34297201-517D4E6C-3B68-4C1D-B70D-395416E8EEB5Q34372394-38422A8D-BA17-4B49-9061-3DE62DDE0C16Q34519785-F90BE0BD-41F5-4874-9430-BC856A784D96Q35119023-0A675DF1-F456-4813-A75D-35B7EA81F3FAQ35176135-5679C550-50F3-40C5-A681-68523A8DB8EEQ35888367-33D9F07C-682C-420E-9F02-FEA878475FC8Q36123609-255038C4-44BF-4ABA-84D4-C73DBFE6C2F6Q36321008-FD4F17DC-FB5D-4F70-83D2-560E37E28F07Q36431597-9D016D61-5AF2-4710-BA50-D6BBB8C17A14Q36653930-3CCB1BC0-77F2-418C-B11C-D774542A2F1EQ36920523-8310C5DD-21E3-40D6-9434-1F11D33DEAA1Q37230276-E2C22C67-AF3B-40D7-A8F8-3AEACC898FB1Q37668486-2F27DAD2-C43F-4653-93BA-B88A0054339AQ37693160-A5ACFE28-A478-40B9-84AB-DC45F3020428Q37700537-55161342-2B9F-4484-9D53-D9842A188088Q37700755-907F8609-668C-4B2D-9FCA-344474D5FFC6Q37854580-159004AD-F5E5-4C36-A81F-0734E63D7BC3Q37923355-45CE85B8-1EF8-475C-BF12-369AE32928BBQ38087506-ED3A0985-80FC-4F31-9A68-9FD736277ADDQ38104674-0EB1F423-019B-4A34-80E1-54402B84BF12Q38150859-E065FBE4-1731-4957-A8F6-5D9ED750E225Q38255698-78A50A88-076E-475D-9D63-F66ABF7E758BQ38763700-C7414B7B-C3D0-44E9-B053-AE790D2D7322Q38974661-B96DE980-2981-4F99-85F5-8CD02317D197Q39663434-AE158DD8-6D3C-4AE9-B549-096B866CB1BAQ40540575-AFE7757E-368D-4C31-B244-84F1FA327AE6Q40787612-9E71C657-AE9D-4756-B34D-5293269EF801Q42056856-686B7685-789C-4130-8FF3-5B78936B5146Q42180857-B363AF5D-FA63-4E35-B307-9BC62CDADB09
P2860
Epoetin-associated pure red cell aplasia: past, present, and future considerations
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 14 May 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Epoetin-associated pure red cell aplasia: past, present, and future considerations
@en
Epoetin-associated pure red cell aplasia: past, present, and future considerations.
@nl
type
label
Epoetin-associated pure red cell aplasia: past, present, and future considerations
@en
Epoetin-associated pure red cell aplasia: past, present, and future considerations.
@nl
prefLabel
Epoetin-associated pure red cell aplasia: past, present, and future considerations
@en
Epoetin-associated pure red cell aplasia: past, present, and future considerations.
@nl
P2093
P2860
P1433
P1476
Epoetin-associated pure red cell aplasia: past, present, and future considerations
@en
P2093
Allen R Nissenson
Charles L Bennett
Denis Cournoyer
Dennis W Raisch
Jerome Rossert
June M McKoy
Nicole Casadevall
Robin E Stonecash
P2860
P304
P356
10.1111/J.1537-2995.2008.01749.X
P577
2008-05-14T00:00:00Z